1072P Patient-reported outcomes (PROs) with 1L pembrolizumab (pembro) + chemotherapy (chemo) then maintenance pembro + olaparib (ola) in advanced BRCA1/2-nonmutated epithelial ovarian cancer (EOC): Phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 study | Publicación